A clinical proof of concept trial to evaluate the safety and efficacy of a single dose level of ORKA-001 versus placebo in patients with moderate-to-severe psoriasis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

24 Dec 2024 New trial record
19 Dec 2024 According to Oruka Therapeutics media release, Oruka plans to initiate a proof-of-concept study of ORKA-001 in moderate-to-severe psoriasis in the second half of 2025 with initial efficacy data expected in the second half of 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com